重症联合免疫缺陷的基因治疗：我们成功了吗？
Gene therapy for severe combined immunodeficiency: are we there yet?
作者信息
Cavazzana-Calvo Marina, Fischer Alain
机构信息
INSERM U768 and Université Paris Descartes, Paris, France.
出版信息
J Clin Invest. 2007 Jun;117(6):1456-65. doi: 10.1172/JCI30953.
Abstract
Inherited and acquired diseases of the hematopoietic system can be cured by allogeneic hematopoietic stem cell transplantation. This treatment strategy is highly successful when an HLA-matched sibling donor is available, but if not, few therapeutic options exist. Gene-modified, autologous bone marrow transplantation can circumvent the severe immunological complications that occur when a related HLA-mismatched donor is used and thus represents an attractive alternative. In this review, we summarize the advantages and limitations associated with the use of gene therapy to cure SCID. Insertional mutagenesis and technological improvements aimed at increasing the safety of this strategy are also discussed.
摘要
造血系统的遗传性和获得性疾病可通过异基因造血干细胞移植治愈。当有人类白细胞抗原（HLA）匹配的同胞供体时，这种治疗策略非常成功，但如果没有，则几乎没有治疗选择。基因修饰的自体骨髓移植可以规避使用相关HLA不匹配供体时出现的严重免疫并发症，因此是一种有吸引力的替代方法。在本综述中，我们总结了与使用基因疗法治疗重症联合免疫缺陷病（SCID）相关的优缺点。还讨论了插入诱变以及旨在提高该策略安全性的技术改进。
相似文献
1
Gene therapy for severe combined immunodeficiency: are we there yet?重症联合免疫缺陷的基因治疗：我们成功了吗？
J Clin Invest. 2007 Jun;117(6):1456-65. doi: 10.1172/JCI30953.
2
[Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].[基因改造细胞移植治疗儿童重症联合免疫缺陷病：巨大希望与近期失望]
Med Wieku Rozwoj. 2003 Jan-Mar;7(1):27-34.
3
Evolving Gene Therapy in Primary Immunodeficiency.原发性免疫缺陷中不断发展的基因治疗
Mol Ther. 2017 May 3;25(5):1132-1141. doi: 10.1016/j.ymthe.2017.03.018. Epub 2017 Mar 31.
4
Gene therapy for adenosine deaminase deficiency.腺苷脱氨酶缺乏症的基因治疗。
Immunol Allergy Clin North Am. 2010 May;30(2):249-60. doi: 10.1016/j.iac.2010.02.003.
5
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.使用假型γ逆转录病毒载体对X连锁重症联合免疫缺陷进行基因治疗。
Lancet. 2004;364(9452):2181-7. doi: 10.1016/S0140-6736(04)17590-9.
6
Advances in the treatment of Chronic Granulomatous Disease by gene therapy.基因疗法治疗慢性肉芽肿病的进展。
Curr Gene Ther. 2007 Jun;7(3):155-61. doi: 10.2174/156652307780859044.
7
Gene therapy for PIDs: progress, pitfalls and prospects.PID 基因治疗：进展、陷阱与展望。
Gene. 2013 Aug 10;525(2):174-81. doi: 10.1016/j.gene.2013.03.098. Epub 2013 Apr 6.
8
Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency.腺苷脱氨酶缺乏症严重联合免疫缺陷的基因治疗进展。
Curr Opin Allergy Clin Immunol. 2010 Dec;10(6):551-6. doi: 10.1097/ACI.0b013e32833fea85.
9
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.腺苷脱氨酶缺乏症严重联合免疫缺陷症的造血干细胞基因治疗可实现长期免疫恢复和代谢纠正。
Sci Transl Med. 2011 Aug 24;3(97):97ra80. doi: 10.1126/scitranslmed.3002716.
10
Gene therapy for SCID--a complication after remarkable progress.重症联合免疫缺陷病的基因治疗——取得显著进展后的一个并发症
Lancet. 2002 Oct 19;360(9341):1185-6. doi: 10.1016/S0140-6736(02)11290-6.
引用本文的文献
1
Translation of unspliced retroviral genomic RNA in the host cell is regulated in both space and time.宿主细胞中未剪接逆转录病毒基因组RNA的翻译在空间和时间上均受到调控。
J Cell Biol. 2025 Apr 7;224(4). doi: 10.1083/jcb.202405075. Epub 2025 Jan 27.
2
Differentiation ability of hematopoietic stem cells and mesenchymal stem cells isolated from human peripheral blood.从人外周血中分离出的造血干细胞和间充质干细胞的分化能力。
Front Cell Dev Biol. 2024 Dec 18;12:1450543. doi: 10.3389/fcell.2024.1450543. eCollection 2024.
3
A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases.一种优化腺相关病毒向脑部递送以治疗神经退行性疾病的多方面方法。
Front Neurosci. 2021 Sep 24;15:747726. doi: 10.3389/fnins.2021.747726. eCollection 2021.
4
Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID.重组激活基因-1缺陷型重症联合免疫缺陷病基因治疗的临床前成功开发
Mol Ther Methods Clin Dev. 2020 Mar 31;17:666-682. doi: 10.1016/j.omtm.2020.03.016. eCollection 2020 Jun 12.
5
Darwinian selection within an individual or somatic selection: facts and models.个体内的达尔文选择或体细胞选择：事实与模型。
J Mol Cell Biol. 2019 Aug 19;11(8):719-722. doi: 10.1093/jmcb/mjz014.
6
ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.ADA 缺乏症：临床和实验室特征及转归评估。
J Clin Immunol. 2018 May;38(4):484-493. doi: 10.1007/s10875-018-0496-9. Epub 2018 May 9.
7
Gene Therapy for Metabolic Diseases.代谢疾病的基因治疗
Transl Sci Rare Dis. 2016;1(1):73-89. doi: 10.3233/TRD-160007.
8
Advances in gene therapy for muscular dystrophies.肌营养不良症基因治疗的进展
F1000Res. 2016 Aug 18;5. doi: 10.12688/f1000research.8735.1. eCollection 2016.
9
Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy.迈向体内扩增：克服造血干细胞在移植和基因治疗应用中的障碍。
World J Stem Cells. 2015 Dec 26;7(11):1233-50. doi: 10.4252/wjsc.v7.i11.1233.
10
[Heterogeneity of hematopoietic stem cell].造血干细胞的异质性
Zhonghua Xue Ye Xue Za Zhi. 2015 Oct;36(10):878-82. doi: 10.3760/cma.j.issn.0253-2727.2015.10.018.
本文引用的文献
1
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.载体整合是非随机且成簇的，并影响X连锁重症联合免疫缺陷病基因治疗中淋巴细胞生成的命运。
J Clin Invest. 2007 Aug;117(8):2225-32. doi: 10.1172/JCI31659.
2
Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).腺苷脱氨酶缺乏症的管理方案；欧洲血液与骨髓移植协会卫星研讨会会议记录（2006年3月，汉堡）
Clin Immunol. 2007 May;123(2):139-47. doi: 10.1016/j.clim.2006.12.009. Epub 2007 Feb 14.
3
Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype.原发性T细胞免疫缺陷患者造血干细胞移植后的长期T细胞重建与髓系嵌合现象有关，可能还与原发性疾病表型有关。
Blood. 2007 May 15;109(10):4575-81. doi: 10.1182/blood-2006-07-029090. Epub 2007 Feb 1.
4
Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.通过移植基因改造的表皮干细胞矫正交界性大疱性表皮松解症。
Nat Med. 2006 Dec;12(12):1397-402. doi: 10.1038/nm1504. Epub 2006 Nov 19.
5
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice.异染性脑白质营养不良的基因治疗可逆转小鼠的神经损伤和缺陷。
J Clin Invest. 2006 Nov;116(11):3070-82. doi: 10.1172/JCI28873.
6
Gene therapy: X-SCID transgene leukaemogenicity.基因治疗：X连锁重症联合免疫缺陷病转基因致白血病性。
Nature. 2006 Sep 21;443(7109):E5-6; discussion E6-7. doi: 10.1038/nature05219.
7
Insulators: exploiting transcriptional and epigenetic mechanisms.绝缘子：利用转录和表观遗传机制
Nat Rev Genet. 2006 Sep;7(9):703-13. doi: 10.1038/nrg1925. Epub 2006 Aug 15.
8
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.在停用聚乙二醇化腺苷脱氨酶（PEG-ADA）并采用轻度预处理后，通过干细胞基因疗法成功重建腺苷脱氨酶严重联合免疫缺陷症（ADA-SCID）患者的免疫力。
Mol Ther. 2006 Oct;14(4):505-13. doi: 10.1016/j.ymthe.2006.06.007. Epub 2006 Aug 14.
9
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy.X连锁重症联合免疫缺陷病基因治疗小鼠模型中插入诱变的独特风险因素。
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11730-5. doi: 10.1073/pnas.0603635103. Epub 2006 Jul 24.
10
Targeting lentiviral vectors to specific cell types in vivo.在体内将慢病毒载体靶向特定细胞类型。
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11479-84. doi: 10.1073/pnas.0604993103. Epub 2006 Jul 24.
Zotero 插件